Cite
The myosin II inhibitor, blebbistatin, ameliorates pulmonary endothelial barrier dysfunction in acute lung injury induced by LPS via NMMHC IIA/Wnt5a/β-catenin pathway.
MLA
Zhang, Jiazhi, et al. “The Myosin II Inhibitor, Blebbistatin, Ameliorates Pulmonary Endothelial Barrier Dysfunction in Acute Lung Injury Induced by LPS via NMMHC IIA/Wnt5a/β-Catenin Pathway.” Toxicology & Applied Pharmacology, vol. 450, Sept. 2022, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.taap.2022.116132.
APA
Zhang, J., Pan, Z., Zhou, J., Zhang, L., Tang, J., Gong, S., Li, F., Yu, B., Zhang, Y., & Kou, J. (2022). The myosin II inhibitor, blebbistatin, ameliorates pulmonary endothelial barrier dysfunction in acute lung injury induced by LPS via NMMHC IIA/Wnt5a/β-catenin pathway. Toxicology & Applied Pharmacology, 450, N.PAG. https://doi.org/10.1016/j.taap.2022.116132
Chicago
Zhang, Jiazhi, Ziqian Pan, Jianhao Zhou, Ling Zhang, Jiahui Tang, Shuaishuai Gong, Fang Li, Boyang Yu, Yuanyuan Zhang, and Junping Kou. 2022. “The Myosin II Inhibitor, Blebbistatin, Ameliorates Pulmonary Endothelial Barrier Dysfunction in Acute Lung Injury Induced by LPS via NMMHC IIA/Wnt5a/β-Catenin Pathway.” Toxicology & Applied Pharmacology 450 (September): N.PAG. doi:10.1016/j.taap.2022.116132.